Active Biotech to present at SG Cowen & Co. 25th Annual Health Care Conference
The conference will give institutional investors direct contact with the companies. From Active Biotech will be present; Sven Andréasson, CEO, and Tomas Leanderson, CSO.
The presentation, scheduled to take place on Tuesday, March 15 at 11:20 am -12:00 pm will include the development of Active Biotech's oral MS drug (laquinimod) that is ongoing in partnership with Teva Pharmaceutical Industries, a novel concept for the treatment of lung cancer (ANYARA) as well as an update of the other clinical projects. A live and archived web cast will be available at www.activebiotech.com
and at www.sgcowen.com.
For more details about Active Biotech and ongoing projects, please visit our web page www.activebiotech.com
Lund, March 10, 2005
Active Biotech AB (publ)
President & CEO
Active Biotech AB is a biotechnology company focusing on research and development of pharmaceuticals. Active Biotech has a strong R&D portfolio and pipeline products with focus on autoimmune/inflammatory diseases and cancer. Most advanced project is laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, as well as a novel concept for use in cancer immunotherapy, ANYARA (TTS).
Active Biotech AB
P.O. Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 20 50